“We have laid a strong and exciting foundation for Immunovant,” said Pete Salzmann, M.D., chief executive officer at Immunovant. “We believe our initial Phase 1 data for IMVT-1402 in healthy adults supports its potential best-in-class profile, and we are actively designing potential registrational programs across a range of different indications. We look forward to sharing more details of the development plan for IMVT-1402, as well as key data readouts from batoclimab trials in neurology over the course of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMVT:
- The biotech stocks to own in 2024, according to Piper Sandler
- Immunovant price target raised to $52 from $47 at Stifel
- Immunovant price target raised to $51 from $49 at BofA
- Immunovant price target raised to $51 from $47 at H.C. Wainwright
- Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
